Skip Navigation


Rheumatology Advance Access originally published online on February 3, 2005
Rheumatology 2005 44(5):691-693; doi:10.1093/rheumatology/keh556
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
44/5/691    most recent
keh556v2
keh556v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Claus, R.
Right arrow Articles by Lorenz, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Claus, R.
Right arrow Articles by Lorenz, P.
Related Collections
Right arrow Pregnancy and Rheumatic Diseases
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oupjournals.org

LETTER TO THE EDITOR

Congenital heart block associated with a maternal anti-HsEg5-like autoantibody

R. Claus, U. Lenschow1, T. Külz2, A. Kotitschke, D. Meiske, H.-J. Thiesen and P. Lorenz

Departments of Immunology, 1 Pediatrics and 2 Obstetrics and Gynecology, University of Rostock, Rostock, Germany

Correspondence to: R. Claus, Institute of Immunology, University of Rostock, Schillingallee 70, 18057 Rostock, Germany. E-mail: renate.claus@med.uni-rostock.de

The first 10% of the full text of this article appears below.

SIR, Congenital heart block (CHB) is a rare (1:20 000) disease, and in 70% of cases there are no coexisting cardiac malformations [1]. In this subsect, up to 90% [2, 3] are associated with, if not directly caused by, maternal autoantibodies (Abs) against SSA/SSB (cardiac manifestation of neonatal lupus erythematosus), independently of whether maternal SLE or SS is manifested. Via active placental transfer (increasing after 16 weeks' gestation), IgG antibodies (Abs) gain access to the fetal heart during a vulnerable phase (from week 16 until shortly after birth), when the main cardiac development is complete and physiological apoptotic events prevail. Damage to . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?